Medivir appoints Charlotte Edenius
pharmafile | November 3, 2010 | Appointment | Research and Development | Charlotte Edenius, Medivir, appointment, research and development
Swedish specialty pharmaceutical company Medivir has appointed Charlotte Edenius to the newly created position of VP of research and development projects.
She will have responsibility for Medivir’s project portfolio and become a member of the company’s management.
Charlotte joins Medivir from Swedish pharmaceutical company Orexo, where she was chief scientific officer, and her previous positions also include chief scientific officer of Biolipox and various executive positions in experimental medicine and clinical R&D at AstraZeneca.
Medivir’s chief science officer Bertil Samuelsson said: “I’m very pleased to bring Charlotte Edenius into Medivir in this position as vice president, research and development projects where she will bring key competence to our projects.
“Her very extensive and in-depth knowledge of the life sciences sector, from the research side, preclinical and clinical development, will also reinforce our strategic endeavor to become a profitable medium-sized company within a five-year period, with high growth and a focus on infectious diseases.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






